Tegoprubart

Data from eight participants continue to support safety and tolerability profile of tegoprubart Mean eGFR increased over the measurement period, from 67.0 mL/min/1.73 m² at 12 months to 74.2 mL/min/1.73 m² at 24 months IRVINE, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that it will present 24-month follow-up data from eight patients enrolled in the Phase 1b trial long-term extension evaluating tegoprubart in kidney transplantation at the American Society of Transplant Surgeons Winter Symposium, taking place January 23–25, 2026, in Scottsdale, Arizona. There were no episodes of biopsy-proven acute rejection, graft loss, death, new-onset diabetes mellitus, or de novo donor-specific antibody formation during the study period. Mean estimated glomerular filtration rate (eGFR) increased over the measurement period, from 67.0 mL/min/1.73 m² at 12 months to 74.2 mL/min/1.73 m² at 24 months. Details on the poster presentation are below: Title: Long-Term Outcomes of a Phase 1, Single Arm Cohort of De Novo Kidney Transplant Recipients Treated with Tegoprubart, an Anti-CD40L Antibody, as the Core Immunosuppression Regimen Poster: #62 Session Title: Poster Session B Date: Friday, January 23, 2026, from 5:45 - 7:15 p.m. PT Following the presentation, a copy of the poster will be available in the Investors section of the Company’s website at https://ir.eledon.com/news-and-events/publications-and-presentations. About Eledon Pharmaceuticals and tegoprubart Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, islet cell transplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com. Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter Forward-Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. Any statements about the company’s future expectations, plans and prospects, including statements about planned clinical trials, the development of product candidates, as well as other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “estimates,” “intends,” “predicts,” “projects,” “targets,” “looks forward,” “could,” “may,” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently uncertain and are subject to numerous risks and uncertainties, including: our short operating history and shifts in our business strategy; our operating losses since inception; our need for additional funding to develop our lead drug candidate and our ability to secure additional funding on acceptable terms or at all; the impact of issuances of our common stock, including in the possibility of dilution or a decline in our stock price; our ability to successfully develop our product candidates; unfavorable global economic and financial market conditions; the regulatory environment of our business and our ability to obtain required regulatory approvals; results of non-clinical studies and clinical trials, and risks that non-clinical studies or early clinical trials may not be predictive of results of later-stage clinical trials; delays or difficulties in enrollment of patients in clinical trials; our ability to attract and retain our executives and key employees; legislation of the pharmaceutical and healthcare industries; cybersecurity and data privacy risks; the ability of our products to achieve marketing approval; competition in our industry; our ability to obtain insurance coverage; our dependence on contract research organizations; our ability to protect our intellectual property; public health crises; our ability to establish and maintain proper and effective internal control over financial reporting and other risks disclosed in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed with the Securities and Exchange Commission on November 14, 2025. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors. These risks and uncertainties, as well as other risks and uncertainties that could cause the company’s actual results to differ materially from the forward-looking statements contained herein, are discussed in our quarterly 10-Q, annual 10-K, and other filings with the U.S. Securities and Exchange Commission, which can be found at www.sec.gov. Any forward-looking statements contained in this press release speak only as of the date hereof and not of any future date, and the company expressly disclaims any intent to update any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Contact: Stephen Jasper Gilmartin Group (858) 525 2047 stephen@gilmartinir.com Media Contact: Jenna Urban CG Life (212) 253 8881 jurban@cglife.com Source: Eledon Pharmaceuticals Source: Eledon Pharmaceuticals, Inc.

Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, Dec. 31, 2025 /PRNewswire/ -- USA News Group News Commentary – Recent clinical trials achieving 83% insulin independence rates have ignited a dramatic shift in metabolic disease investment[1], with late-2025 M&A activity reaching record valuations as major pharmaceutical companies race to secure curative platforms over symptom-management franchises[2]. This pivot toward functional cures rather than chronic insulin dependence is defining the strategic roadmaps of Avant Technologies, Inc. (OTCQB: AVAI), Novo Nordisk A/S (NYSE: NVO), Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN), Viking Therapeutics, Inc. (NASDAQ: VKTX), and Tandem Diabetes Care, Inc. (NASDAQ: TNDM). Analysts project the regenerative medicine market will surge from $37.98 billion in 2025 to $88.85 billion by 2030, driven by curative cell therapies now entering pivotal trials[3]. Meanwhile, FDA expedited review pathways have awarded over 350 designations across diabetes and metabolic diseases in the past three years[4], compressing clinical timelines by 30% and creating an urgent investment window as breakthrough therapies race toward commercial launch. Avant Technologies, Inc. (OTCQB: AVAI) is developing cell-based therapies for diabetes, aging, and chronic diseases using a proprietary encapsulation technology that protects genetically modified therapeutic cells from immune rejection. The company operates through two strategic joint ventures focused on addressing massive global health markets. The first, Insulinova, Inc., is a partnership with SGAustria Pte. Ltd., through which Avant is developing treatments for type 1 and insulin-dependent type 2 diabetes. The approach centers on a cell encapsulation technology that allows genetically modified insulin-producing cells to survive long-term in the body without being susceptible to any immune system attacks. This solves a fundamental problem that historically required patients to take lifelong immunosuppressive drugs with serious side effects. "Cell encapsulation is a game-changer in the field of regenerative medicine," said Chris Winter, CEO of Avant Technologies. "By partnering with SGAustria, we're ensuring that any genetically modified insulin-producing cells that we develop together can thrive in the body long-term and offer the potential of restoring natural glucose control and dramatically improving patients' quality of life. This technology not only minimizes risks like immune rejection but also prevents potential complications such as cell escape or tumor formation, making it a cornerstone for safe and scalable diabetes therapies." The diabetes market represents a substantial opportunity. According to the International Diabetes Federation, 589 million people globally live with type 1 and insulin-dependent type 2 diabetes, projected to reach 853 million by 2050. SGAustria's Cell-in-a-Box® technology creates a protective barrier around genetically modified cells, shielding them from any immune response while allowing nutrients, oxygen, and insulin to pass through freely. Avant's second joint venture, Klothonova, partners with Singapore-based Austrianova to develop anti-aging therapies and treatments for age-related diseases that restore circulating α-Klotho levels using genetically modified human cells that overexpress the Klotho protien. Research from the Mayo Clinic shows declining α-Klotho levels are associated with arterial stiffness, endothelial dysfunction, and vascular calcification. Both joint venture projects will utilize cell-encapsulation platforms backed by over 50 publications representing decades of development. The potential market spans multiple therapeutic areas: the global Alzheimer's market is projected to reach $32.8 billion by 2033, cardiovascular disease remains the world's leading cause of death, and kidney disease affects 850 million people worldwide. CONTINUED… Read this and more news for Avant Technologies Inc. at and Novo Nordisk (NYSE: NVO) submitted a New Drug Application to the FDA for once-weekly CagriSema (cagrilintide 2.4 mg and semaglutide 2.4 mg), the first injectable GLP-1 receptor agonist and amylin analogue combination for weight management. In the REDEFINE 1 phase 3 trial, adults with obesity or overweight with weight-related comorbidities taking CagriSema lost an average of 23% body weight when evaluating the treatment effect if all patients stayed on treatment, with 54% of patients with obesity at baseline reaching BMI below 30 kg/m2 at week 68. The trial included 3,417 adults with 87.4% of patients on steroids at baseline successfully tapering to prednisone 5 mg per day or less by Week 24. The FDA is expected to review the CagriSema application in 2026, with Health Canada granting the first approval outside the U.S. in August 2025. Potential approvals are anticipated in the United Kingdom and Australia in the first half of 2026 and Switzerland in 2027, while Novo Nordisk finalizes a strategy with the European Medicines Agency to support EU marketing authorization. Eledon Pharmaceuticals (NASDAQ: ELDN) recently announced preliminary data from six patients with Type 1 diabetes treated with tegoprubart following islet transplantation at UChicago Medicine. All six subjects achieved insulin independence after one or two transplants, with one patient maintaining HbA1c as low as 4.7% for over 15 months without exogenous insulin. Tegoprubart was well tolerated with no serious infections, thromboembolic events, or kidney and neurological toxicity commonly seen with calcineurin inhibitors. "For years, clinicians have been working to find a new medication that can prevent rejection of islet cells while offering a better safety profile than calcineurin inhibitors including tacrolimus, which remain the current standard of care but are often associated with debilitating metabolic, neurologic, and cardiovascular toxicities," said Piotr Witkowski, M.D., Ph.D., Director of the Pancreas and Islet Transplant Program at UChicago Medicine. "These preliminary data in the first six subjects with T1D are very encouraging, with all six subjects achieving insulin independence." The trial has been extended to 12 subjects, and Breakthrough T1D has committed to fund a second study in T1D patients with chronic kidney disease. Eledon is developing tegoprubart as a tacrolimus-free immunosuppression regimen for preventing transplant rejection. Viking Therapeutics (NASDAQ: VKTX) announced completion of enrollment ahead of schedule in its Phase 3 VANQUISH-1 trial evaluating subcutaneous VK2735, a dual GLP-1/GIP receptor agonist, for treating obesity. The 78-week study enrolled approximately 4,650 adults with obesity or who are overweight with weight-related comorbidities, exceeding the target enrollment. The trial is evaluating weekly VK2735 doses of 7.5 mg, 12.5 mg, and 17.5 mg compared to placebo, with a primary endpoint of percent change in body weight from baseline at 78 weeks. "We are excited to announce completion of enrollment in VANQUISH-1 ahead of schedule," said Brian Lian, Ph.D., CEO of Viking. "As with prior VK2735 studies, the trial accrued rapidly and exceeded our enrollment target. We believe this speaks to the enthusiasm for new obesity treatments beyond those currently available." The company expects to complete enrollment in its Phase 3 VANQUISH-2 study of VK2735 in patients with type 2 diabetes and obesity in the first quarter of 2026. VK2735 demonstrated up to 14.7% mean body weight reduction with no signs of plateau in the Phase 2 VENTURE study, along with encouraging safety and tolerability. Tandem Diabetes Care (NASDAQ: TNDM) has launched its t:slim mobile application in Canada for both Android and iOS users, enabling patients to deliver boluses from compatible smartphones and wirelessly upload pump data to the cloud-based Tandem Source platform. The secure application displays the last 24 hours of glucose trends, pump status changes, insulin therapy data, and pump alerts while maintaining the t:slim X2 insulin pump's independent functionality. Users can view pump information and program requests from either their pump or smartphone. "With this release, we are furthering our commitment to expand our innovative, integrated solutions to customers worldwide," said John Sheridan, president and CEO of Tandem Diabetes Care. "We are thrilled to be able to bring the benefits of the Tandem t:slim mobile app to our customers in Canada for both iOS and Android devices." The mobile app is available for download on the Apple App Store and Google Play, with eligible customers receiving email instructions for setup. Users must have t:slim X2 insulin pump version 7.8.1 or above to pair their pump with a compatible smartphone and begin using the application. Source: CONTACT: USA NEWS GROUP [email protected] (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. SOURCES CITED: 1. 2. 3. 4. Logo - 21% more press release views with Request a Demo